Introduction Polyamine analogues have demonstrated signiWcant activity against human breast cancer cell lines as single agents as well as in combination with other cytotoxic drugs. This study evaluates the ability of a polyamine analogue N 1 ,N 11 -bis(ethyl)norspermine (BENSpm) to synergize with six standard chemotherapeutic agents, 5-Xuorouracil (FU), Xuorodeoxyuridine, cis-diaminechloroplatinum(II) (C-DDP), paclitaxel, docetaxel, and vinorelbine. Materials and methods Four human breast cancer cell lines (MDA-MB-231, MCF-7, Hs578t, and T47D) and one immortalized, non-tumorigenic mammary epithelial cell line (MCF-10A) were used for in vitro combination studies with BENSpm and cytotoxic drugs. Xenograft mice models generated with MDA-MB-231 cells were used for in vivo studies with BENSpm and paclitaxel. Results and conclusion BENSpm exhibited synergistic inhibitory eVect on cell proliferation in combination with 5-FU or paclitaxel in human breast cancer cell lines (MDA-MB-231 and MCF-7) and was either antagonistic or less eVective in the non-tumorigenic MCF-10A cell line. Synergism was highest with 120 h concomitant treatment or pretreatment with BENSpm for 24 h followed by concomitant treatment for 96 additional hours. Since the cytotoxic eVects of many polyamine analogues and cytotoxic agents are believed to act, in part, through induction of the polyamine catabolic enzymes SSAT and SMO, the role of these enzymes on synergistic response was evaluated in MDA-MB-231 and MCF-7 treated with BENSpm and 5-FU or paclitaxel. Combination treatments of BENSpm with 5-FU or paclitaxel resulted in induction of SSAT mRNA and activity in both cell lines compared to either drug alone, while SMO mRNA and activity were increased only in MDA-MB-231 cells. Induction was greater with BENSpm/ paclitaxel combination than BENSpm/5-FU. Further, RNAi studies demonstrated that both SSAT and SMO play a signiWcant role in the response of MDA-MB-231 cells to treatment with BENSpm and 5-FU or paclitaxel. In MCF-7 cells, only SSAT appears to be involved in the response to these treatments. In an eVort to translate combination studies from in vitro to in vivo, and to form a basis for clinical setting, the in vivo therapeutic eYcacy of BENSpm alone and in combination with paclitaxel on tumor regression was evaluated in xenograft mice models generated with MDA-MB-231 cells. Intraperitoneal exposure to BENSpm or taxol singly and in combination for 4 weeks resulted in signiWcant inhibition in tumor growth. These Wndings help elucidate the mechanisms involved in synergistic drug A. Pledgie-Tracy, M. Billam contributed equally to this work.
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Introduction
Metastatic breast cancer is the second leading cause of cancer death among women in the United States despite substantive advances in the Weld. One of the major obstacles in treating breast cancer is that tumors that are initially responsive to systemic treatments often progress into a more resistant form that does not respond well to current therapies [46] . Nearly 75% of patients with axillary-positive nodes and 30% of patients with axillary-negative nodes will eventually relapse with metastatic disease in the absence of systemic therapy; current adjuvant approaches provide moderate improvement in outcomes [21] . Therefore, alternative therapies are being investigated that may be eVective against breast cancer regardless of its hormone dependency or stage [23] .
Combination chemotherapy is now considered one of the mainstays of the treatment of breast cancer [45, 67] . Several novel agents that target speciWc pathways are being investigated for their eYcacy in combination with standard chemotherapeutic agents [21, 35, 44, 45, 50] . Polyamine analogues are one such class of agents that have shown very promising anti-tumor activity in several in vitro and in vivo models [6, 15, 24, 40, 41, 52, 53, 58, 59, 62] . The natural polyamines are small, ubiquitous polycations that are essential for normal cell growth [14, 69] . Their metabolism is regulated at multiple levels including biosynthesis, catabolism, import, and export [71] . The key, rate-limiting biosynthetic enzymes are ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (AdoMetDC). The polyamine catabolic enzymes act through two pathways: (1) a two-step process involving acetylation by spermidine/ spermine N 1 -acetyltransferase (SSAT) followed by oxidation by N 1 -acetylpolyamine oxidase (APAO), and (2) the direct oxidation of polyamines by spermine oxidase (SMO) [31, 42, 71] . The natural polyamines have multiple feedback mechanisms to regulate their intracellular levels including activation of the catabolic enzymes, decreased polyamine import, and increased polyamine export. Polyamine analogues have been developed to mimic the natural polyamines and alter their normal function with the goal of inhibiting proliferation and/or inducing apoptosis [4, 39, 49, 55] .
A polyamine analogue that has shown signiWcant activity against human breast cancer cells in vitro and in vivo is N 1 ,N 11 -bis(ethyl)norspermine, BENSpm (also known as DENSpm) [14, 23, 24, 41, 71] and it has been examined in Phase I and II clinical studies [34, 74] . Results from the Phase II study of BENSpm for women with advanced refractory breast cancer revealed that, although BENSpm was not active as a single agent in the dose and schedule chosen, this analogue could be safely administered [74] .
The ability of natural polyamines to bind to and alter the conformation of DNA led to studies investigating the potential of polyamine analogues to interact with DNA. In fact, polyamine analogues were found to result in DNA strand breaks [42] , inhibit nucleosome formation in cellfree systems and alter the structure of chromatin and inXuence gene expression in cellular systems [2, 3, 27, 65] . Based on the hypothesis that polyamine analogues can synergize with standard DNA-reactive cytotoxic drugs, several studies evaluated the combination of chemotherapeutic agents with either polyamine analogues or drugs targeting the polyamine metabolic pathway [16, 22, 25, 33, 43, 47, 61, 63, 64, 68, 77] . The Wndings from these studies overall were mixed with results being agent-, schedule-, and cellline-dependent. Additionally, many of these studies were limited in the number of cell lines examined or the examination of their eVects on normal cell lines or tissues. A more thorough examination of diVerent treatment regimens in both tumorigenic and non-tumorigenic cell lines is required to focus in vivo clinical testing.
The cytotoxic eVects of many polyamine analogues, including BENSpm, are believed to act, in part, through induction of SSAT and/or SMO [13, 24, 26, 58] . Several recent studies have also implicated SSAT in the response of cancer cell lines to chemotherapeutic agents. SSAT regulates cellular polyamine homeostasis and SSAT induction results in signiWcantly altered polyamine metabolism. One study using DNA microarray technology identiWed SSAT as one of the most up-regulated genes in MCF-7 breast cancer cells treated with 5-FU [51] . A separate study reported that treatment of A2780 ovarian cancer cells with oxaliplatin or cisplatin synergistically induces SSAT mRNA expression [36, 37, 70] .
The encouraging in vitro and in vivo studies with BENSpm combined with its safety in administration in Phase II clinical studies make this polyamine analogue appealing to examine in combination with traditional cytotoxic drugs. In this study, the ability of BENSpm to synergize with six standard chemotherapeutic drugs (5-Xuorouracil (FU), Xuorodeoxyuridine, cis-diaminechloroplatinum(II) (DDP), paclitaxel, docetaxel, and vinorelbine) using three treatment schedules was examined in four human breast cancer cell lines and one immortalized non-tumorigenic mammary epithelial cell line. The chemotherapeutic agents used in this study were chosen because they are all currently used in the treatment of breast cancer and they represent a wide spectrum of mechanisms of action. The in vitro results suggested combinations for examination in an in vivo model and translation of these synergistic combination treatments to a xenograft mouse model of MDA-MB-231 led to signiWcant tumor regression. These Wndings help further elucidate the mechanism involved in the synergistic drug response and will aid in the design of more useful combinations for the treatment of breast cancer.
Materials and methods

Cell lines and culture conditions
The acquisition and maintenance of the breast cancer cell lines, MDA-MB-231, Hs578t, MCF-7, and T47D, have been previously described [33] . MCF-10A cells were cultured in DMEM/F-12 (Mediatech, Herndon, VA, USA) supplemented with 5% heat-inactivated horse serum (Mediatech), 10 g/mL insulin (Sigma, St Louis, MO, USA), 100 ng/mL cholera toxin (Sigma), 0.5 g/mL hydrocortisone (Sigma), and 20 ng/mL recombinant EGF (Sigma). The SMO stable siRNA clones were generated by annealing and inserting the following oligonucleotides (Invitrogen, Carlsbad, CA, USA) into the pSilencer 2.1-U6 neo expression vector (Ambion, Austin, TX, USA) according to the manufacturer's instructions: SMO Forward, 5Ј GAT CCG CAC TTC TTG AGC  AGG GTT TTC AAG AGA AAC CCT GCT CAA GAA  GTG CTT TTT TGG AAA  SMO Reverse, 5Ј AGC TTT TCC AAA AAA GCA  CTT CTT GAG CAG GGT TTC TCT TGA AAA CCC  TGC TCA AGA AGT GCG The following oligonucleotides (Invitrogen) targeting the SSAT gene were annealed to form the hairpin siRNA template insert that was then ligated into the pSilencer 2.1-U6 hygro expression vector (Ambion) according to the manufacturer's instructions:
SSAT Forward, 5Ј GAT CCG TGA TCC TCC CAC  CTC AGC TTC AAG AGA GCT GAG GTG GGA GGA  TCA CTT TTT TGG AAA  SSAT Reverse, 5Ј AGC TTT TCC AAA AAA GTG  ATC CTC CCA CCT CAG CTC TCT TGA AGC TGA  GGT GGG AGG ATC ACG Lipofectamine was used to transfect 4 g of the targeting plasmid or a nonsense control plasmid (Ambion) into MDA-MB-231 and MCF-7 cells. Single clones representing MDA-MB-231 nonsense control, MDA-MB-231 SMO, MDA-MB-231 SSAT, MDA-MB-231 SMO/SSAT, MCF-7 nonsense control, MCF-7 SMO, MCF-7 SSAT, and MCF-7 SMO/SSAT were chosen. Clones were selected and maintained in DMEM (Mediatech) supplemented with 5% FBS (Mediatech), 1% glutamine (Mediatech), and 500 g/ml G418 (Sigma) or 500 g/ml hygromycin (Roche) as required.
Reagents
BENSpm was synthesized as described previously [4] . A concentrated stock solution of 10 mM was prepared in water and was stored at ¡20°C. 5-FU was obtained from the Johns Hopkins Oncology Center pharmacy and was stored in water at ¡20°C. Paclitaxel (a gift from BristolMyers/Squibb) was stored at 4°C as a 10-mM solution in DMSO. All drugs were diluted in cell culture medium to the desired Wnal concentration except for docetaxel, which was initially diluted in water and then in cell culture medium. 5-(and -6)-chloromethyl-2Ј,7Ј-dichlorodihydroXuorescein diacetate (CM-H 2 DCFDA), mixed isoforms, was purchased from Molecular Probes (Eugene, OR, USA) and catalase was purchased from Sigma. Structures for agents used are shown in Fig. 1 .
MTT and cell growth assays
MTT assays were performed as described previously [33] . BrieXy, cells were plated in 96-well dishes and were treated as outlined below. All experiments were performed at least three times in quadruplicate. The results from the MTT assays were validated by direct comparison to a conventional cell growth assay. For the cell growth assay, cells were plated at a cell density of 5,000 cells/well in six-well tissue culture plates. After attachment overnight, the medium was replaced and cells were treated as described below. At the end of the treatment period, cells were detached by trypsinization and counted using a Coulter particle counter.
Treatment schedules
Three diVerent treatment schedules were used to mimic potentially relevant clinical schedules that have been successfully examined in vivo [33] . The Wrst treatment schedule evaluated simultaneous exposure to both the polyamine analogue and cytotoxic drug for 120 h. In the second treatment schedule, the cells were exposed to 24 h treatment with the cytotoxic drug alone followed by treatment with medium containing polyamine analogue for additional 96 h. In both treatment schedules, medium was discarded after 24 h and the cell monolayer was washed with drugfree medium, and fresh medium containing either cytotoxic drug and polyamine analogue or only the polyamine analogue was added for 96 h. The third treatment schedule used 24 h polyamine analogue treatment followed by removal of the medium and addition of medium containing both the polyamine analogue and cytotoxic drug for 96 h. A lengthy treatment with the polyamine analogue was used for all treatment schedules because previous studies have demonstrated that sustained exposure is required for optimal polyamine analogue activity [4] .
Median eVect/combination index analysis
The median eVect/combination index (CI) model was used to determine synergy, additivity, or antagonism of the combination treatments [19] . Cell cultures were treated with each agent individually at its IC 50 concentration and at Wxed multiples (two and three times) and fractions (0.75, 0.50, and 0.25) of the IC 50 concentrations [33] . The agents (polyamine analogue and cytotoxic drug) were also combined in these same dose-Wxed ratios to determine the CI. Synergy was deWned as any CI value below 1, additivity as CI = 1, and antagonism as any CI above 1 § SD. Experiments were done in quadruplicate, and each experiment yielded one CI value. The CI values shown represent the mean § SD for at least three, independent experiments. CI values are shown only for fractional growth inhibition levels of 0.50, 0.75, and 0.90. RNA isolation, RT, and real-time PCR Total cellular RNA was isolated from cultured cell lines using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. cDNA was synthesized from 3 g of total RNA using MMLV reverse transcriptase (Invitrogen) and oligo-dT primers (Invitrogen). For Real Time PCR, cDNA was ampliWed using SYBR green (Sigma) using the following primers:
Real Time PCR data were acquired and analyzed using Sequence Detector v1.7 software (Perkin Elmer, Wellesley, MA, USA) and were normalized to the GAPDH housekeeping gene. All experiments were performed four times in duplicate.
Analysis of SSAT and oxidase activity SSAT activity was determined by using C 14 -labeled substrates and by scintillation counting of end products produced as previously described [11] . Protein concentrations were determined using the Bradford method [8] . SMO and APAO enzyme activity in cell lysates was assayed as described previously using either 250 M spermine or N 1 -acetylspermine, respectively, as the substrate (Sigma, St Louis, MO, USA) as a substrate [8] . All activity experiments were repeated at least three times in triplicate.
Xenograft mice model and treatment schedules
Four-six-week old oophorectomized female Balb/c athymic nu/nu mice (Harlan Sprague-Dawley, Madison, WI, USA) were injected sub-cutaneously (s.c.) in the right Xank with 1.5 £ 10 6 MDA-MB-231 cells in a volume of 100 l Hanks Balance Salt Solution (HBSS). As the tumors were established (30 mm 3 ), the mice were randomized into four groups (n = 10/group), control, BENSpm, paclitaxel and BENSpm/paclitaxel. While the control mice received intraperitoneal (i.p.) injection of HBSS (5 times/week) and HBSS with cremophor (once weekly), the three treatment groups received: group (1) 100 mg/kg BENSpm i.p. 5 days each week for 4 weeks, group (2) 5 mg/kg paclitaxel (cremophor used as excipient) i.p. once weekly for 4 weeks, and (3) BENSpm and paclitaxel. Tumors were measured with a caliper once weekly and tumor volume was calculated according to the formula, volume = length £ width £ height £ 0.5236. Animals were monitored carefully for signs of toxicity and weighed once weekly. All mice were humanely euthanized at the end of experiment.
Statistics
Time to 6-fold tumor increase relative to baseline was evaluated to assess the eVects of two drugs (BENSpm or paclitaxel) and the combination (BENSpm and paclitaxel) on tumor growth inhibition. Death prior to the target tumor increase was a competing risk. Since censoring deaths from competing causes means that fewer animals at risk and impact of time-to-manifold tumor progression is overestimated due to the decreased denominator, a cumulative incidence function was used to account for the presence of a competing risk and obtain more precise estimates. Animals that were still alive at the end of the study but not yet had reached the target tumor volume were censored at the time of study end. None of the animals had to be sacriWced before reaching the 6-fold tumor increase. DiVerence in cumulative incidence functions between the treatment groups was compared using Gray's method [30] and hazard ratios were estimated using a proportional hazards model of a competing risk described by Fine and Gray [28] . All tests were two-sided and considered statistically signiWcant at P < 0.05. The competing risk analyses were implemented in R software package (v 2.4.1).
Results
EVect of BENSpm and chemotherapeutic drugs on MDA-MB-231 and MCF-7 cell proliferation
The initial combination studies were performed using estrogen receptor (ER)-negative MDA-MB-231 and ER-positive MCF-7 cells as they are representative of both hormoneindependent and hormone-dependent breast cancer. Six chemotherapeutic agents (FdURd, 5-FU, C-DDP, paclitaxel, docetaxel, and vinorelbine) were tested in combination with BENSpm in both cell lines. The chemotherapeutic drugs used were selected because they all have antitumor activity in breast cancer, are currently in use in the treatment of breast cancer, and represent a broad spectrum of mechanisms of action. The symmetrically substituted polyamine analogue BENSpm was chosen for study because it induces SSAT and SMO in breast cancer cell lines and has been evaluated in Phase I and II clinical trials [34, 57, 74] . Three diVerent treatment schedules were examined that are potentially clinically relevant: simultaneous exposure to both polyamine analogue and cytotoxic drug for 120 h; cytotoxic drug exposure for 24 h followed by polyamine analogue exposure for 96 h; and polyamine analogue alone for 24 h followed by simultaneous exposure for 96 h. The CI values for the combination studies using BENSpm with chemotherapeutic drugs were determined for MDA-MB-231 (Table 1) and MCF-7 (Table 2 ) cells using the median eVect/CI model [19] . The two treatment schedules that allowed for the greatest amount of synergy in both cell lines were 120 h concomitant treatment and pre-treatment with BENSpm for 24 h followed by simultaneous treatment for an additional 96 h. Using a concomitant treatment schedule, BENSpm was synergistic with FdURd, 5-FU, C-DDP, and paclitaxel and was primarily additive with docetaxel and vinorelbine (Table 1) . Similar results were obtained when MDA-MB-231 cells were pre-treated with BENSpm followed by simultaneous treatment, although the concomitant treatment schedule was slightly more synergistic. In MCF-7 cells, BENSpm was synergistic with 5-FU and paclitaxel using a concomitant treatment schedule ( Table 2 ). In contrast to the MDA-MB-231 cells, pre-treatment of MCF-7 cells with BENSpm resulted in synergy with agents, including FdURd, 5-FU, paclitaxel, and docetaxel. Pre-treatment with the chemotherapeutic drug followed by BENSpm alone produced mostly additive or antagonistic eVects overall in both cell lines (Tables 1, 2 ). In general, the greatest amount of synergy in both cell lines was observed with BENSpm in combination with 5-FU and paclitaxel using a 120-h simultaneous treatment regimen.
EVects of BENSpm and chemotherapeutic drugs on Hs578t, T47D, and MCF-10A cells
The activity of BENSpm in combination with all six chemotherapeutic drugs was then examined in two other breast cancer cell lines, ER-negative Hs578t and ER-positive T47D, and an immortalized non-tumorigenic mammary epithelial cell line, MCF-10A. Using the 120 h concomitant treatment schedule in Hs578t cells, BENSpm was synergistic with FdURd, 5-FU, and paclitaxel (Table 3) . Further BENSpm was synergistic with FdURd, 5-FU, C-DDP, paclitaxel, and vinorelbine in T47D cells. In MCF-10A cells, all of the chemotherapeutic agents were antagonistic with BENSpm except for paclitaxel; this combination was synergistic although the CI value was greater than that of the cancer cell lines examined. In general, the greatest synergy was observed using BENSpm in combination with 5-FU and paclitaxel in Hs578t and T47D cells.
EVects of pre-treatment with BENSpm followed by concomitant treatment with FdURd, 5-FU, or paclitaxel on Hs578t, T47D, and MCF-10A cells
Next, the activity of BENSpm with FdURd, 5-FU, and paclitaxel was examined in Hs578t, T47D, and MCF-10A cells that were pre-treated with BENSpm followed by simultaneous treatment (Table 4) . These agents were chosen because they have shown the greatest amount of synergy overall with BENSpm and this treatment schedule was used since it was highly synergistic in MDA-MB-231 and MCF- Many polyamine analogues and chemotherapeutic agents act, in part, through the induction of the polyamine catabolic enzymes SSAT and SMO [11, 12, 17, 24, 26, 37, 51, 58] . We therefore examined the induction of both of these enzymes to determine if their increase was associated with the synergistic response of breast cancer cell lines to exposure to BENSpm with 5-FU and paclitaxel. MDA-MB-231 and MCF-7 cells were treated with a range of doses (IC 25 , IC 50 , and IC 75 ) of BENSpm, 5-FU, and paclitaxel and real-time PCR and standard enzyme activity assays were performed to determine the eVects on SSAT and SMO mRNA and activity. BENSpm treatment induced SSAT mRNA and enzyme activity in both MDA-MB-231 and MCF-7 cells with a greater induction in MDA-MB-231 cells (Fig. 1) . 5-FU and paclitaxel treatment also induced SSAT mRNA in both cell lines although there was no signiWcant induction of SSAT activity. BENSpm treatment also induced SMO mRNA and activity in a dose-dependent manner in MDA-MB-231 cells (Fig. 2) . 5-FU treatment slightly induced SMO mRNA and activity whereas paclitaxel treatment induced SMO mRNA and activity more than BENSpm. No induction of SMO mRNA or activity was seen in MCF-7 cells. In addition, no APAO activity induction was seen in MDA-MB-231 or MCF-7 cells with any of these agents (data not shown). Treatment of MDA-MB-231 and MCF-7 cells with another chemotherapeutic agent, vinorelbine, did not signiWcantly induce SSAT or SMO mRNA or activity, suggesting that the induction of these enzymes is not solely a stress-response (data not shown).
Synergistic SSAT and SMO mRNA and activity induction with BENSpm and 5-FU or paclitaxel
As most of the regulation of SSAT expression is post-transcriptional, a key question is whether the high induction of SSAT mRNA with 5-FU and paclitaxel treatment can be translated into greater SSAT activity induction by co-treatment with BENSpm. MDA-MB-231 and MCF-7 cells were treated with either BENSpm alone, paclitaxel alone, 5-FU alone, BENSpm and paclitaxel, or BENSpm and 5-FU for 48 h. Real-time PCR and standard activity assays were performed to determine the eVects on SSAT and SMO mRNA and activity (Fig. 3a, b) . In MDA-MB-231 cells, paclitaxel treatment induced the greatest levels of SSAT mRNA among the single treatment groups while the greatest amount of SSAT mRNA induction occurred with the combination of BENSpm and paclitaxel (Fig. 3a) . In MCF-7 cells, 5-FU treatment induced the greatest levels of SSAT mRNA while the combination of BENSpm and 5-FU induced the greatest levels of SSAT mRNA among all of the treatment groups. In both cell lines, the only single agent that induced SSAT activity was BENSpm while the combination of BENSpm with both paclitaxel and 5-FU induced greater activity in MDA-MB-231 cells as compared with BENSpm alone. The combination of BENSpm with 5-FU in MCF-7 cells resulted in approximately twice the amount of SSAT activity induction versus BENSpm alone.
In MDA-MB-231 cells, the greatest SMO mRNA and activity induction with a single cytotoxic agent was also seen with paclitaxel, which was approximately twice the induction seen with BENSpm alone (Fig. 3c) . The greatest induction of mRNA and activity with a combination treatment was observed with BENSpm and paclitaxel with SMO activity induced nearly 20-fold with BENSpm and paclitaxel treatment compared with untreated cells. No SMO mRNA or activity induction was seen in any of the treated MCF-7 cells (Fig. 3c, d ). In addition, no induction of APAO mRNA or activity was seen in either cell line using these treatment schedules (data not shown).
Knockdown of SSAT and SMO reduces the sensitivity of MDA-MB-231 cells to BENSpm and 5-FU or paclitaxel
A fundamental issue is whether SSAT and/or SMO play a role in the antiproliferative eVects of BENSpm with 5-FU or paclitaxel. To address this question, MTT assays were performed using SSAT, SMO, and SSAT/SMO stable knockdown MDA-MB-231 and MCF-7 cells. Transfected 
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Wxed ratios of BENSpm with paclitaxel or 5-FU for 120 h and MTT assays were performed to examine the role that SSAT and SMO play alone and together on the cellular response to these combination treatments (Figs. 4, 5) . When knockdown MDA-MB-231 cells were treated with BENSpm and paclitaxel simultaneously, the knockdown of either SSAT or SMO reduced their sensitivity while the double knockdown cells were even less sensitive to the combination treatment than either single knockdown cell line (Fig. 4a) . In MCF-7 cells, the knockdown of SSAT alone or in combination with SMO modestly reduced their sensitivity to BENSpm and paclitaxel treatment (Fig. 4b) . The sensitivity of MDA-MB-231 cells to the combination of BENSpm and 5-FU was reduced by the knockdown of each enzyme individually and was reduced even more so with their double knockdown (Fig. 5a) . As with BENSpm and paclitaxel, the sensitivity of MCF-7 cells to BENSpm and 5-FU was modestly reduced with the knockdown of SSAT but was not altered by the knockdown of SMO alone.
BENSpm and paclitaxel alone, and in combination, signiWcantly inhibited tumor growth in xenograft mice model. From promising in vitro results it is evident that synergistic cytotoxic response of treatment with BENSpm and 5-FU or paclitaxel is mediated through activation of SSAT and SMO. In particular, MDA-MB-231 cells were more sensitive to concomitant combination treatment with BENSpm and paclitaxel, resulting in activation of both SSAT and SMO. Conversely knock down of either enzyme individually or in combination reduces the sensitivity of MDA-MB-231 cells to treatment.
Based on these results, the potential for synergy between BENSpm and paclitaxel was assessed in the MDA-MB-231 human breast cancer xenograft model. Although BENSpm has not been evaluated in in vivo mouse models of breast cancer, the maximum tolerated dose for BENSpm in MALME-3 melanoma xenografts has previously been established [5] . Based on these and other studies with diVerent human cancer cell line xenograft models, and the dosing schedules in use for clinical trials, the treatment regimen for BENSpm used in an in vivo combination study was 100 mg/kg/day £ 5, for 4 weeks.
Tumor bearing mice were treated with either BENSpm or paclitaxel alone or in combination for a period of 4 weeks. Consistent with previous studies with other xenograft models, BENSpm signiWcantly inhibits the growth of established breast xenograft tumors. At 100 mg/kg/ day £ 5, for 4 weeks, time to 6-fold increase in tumor volume was signiWcantly longer than that in control (hazard ratio = 7.9, 95% CI = 3.1-20.5; P < 0.0001). Similarly, signiWcantly lower incidence rate of 6-fold tumor increase was observed in mice treated with 5 mg/kg paclitaxel alone (hazard ratio = 2.1, 95% CI = 1.0-4.1; P = 0.04). 
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In combination, BENSpm and paclitaxel signiWcantly inhibited tumor growth in comparison to control (hazard ratio = 4.1, 95% CI = 1.7-10.3; P = 0.002) (Fig. 6) . However, no synergy was observed in the animals treated with the combination.
Discussion
Much attention has been focused on developing therapies that combine the use of standard cytotoxic agents with more novel therapies to overcome disease relapse or resistance. One example of a novel therapeutic family is the polyamine analogues, which mimic the natural polyamines in self-regulating roles, but interfere with their normal cellgrowth promoting functions [23, 41, 46] . Polyamine analogues have demonstrated signiWcant activity as single agents in several tumor models [15, 24, 40, 52, 53, 58, 59, 62] . This study examined the activity of a leading polyamine analogue, BENSpm, in combination with multiple chemotherapeutic agents in four human breast cancer cell lines and an immortalized, non-tumorigenic human breast epithelial cell line. C-DDP is a DNA-reactive agent that results in the formation of inter-and intra-strand crosslinks [10] . Paclitaxel, docetaxel, and vinorelbine interfere with tubulin assembly or disassembly and induce G2/M blocks [9, 29] . 5-FU and FdURd are Xuoropyrimidines with multiple mechanisms of action including inhibition of thymidylate synthase (TS) and misincorporation into DNA and/or RNA [48, 54] . 5-FU also induces SSAT expression in a range of colon cancer cell lines including HCT-116 and HT-29 [1, 7, 17, 76] . However, SSAT mRNA induction by 5-FU does not translate into protein unless BENSpm is added [1] . Several clinically relevant treatment schedules were examined in this study. Of the three treatment schedules tested, the two schedules that were most synergistic were simultaneous treatment with the polyamine analogue and cytotoxic drug for 120 h and pre-treatment with the polyamine analogue for 24 h followed by simultaneous treatment for 96 h. The greatest synergy resulted using a concomitant treatment regimen. These Wndings are consistent with previous studies in the HCT-116 colon cancer cell 
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line treated with BENSpm and oxaliplatin where the combination resulted in massive induction of SSAT activity and mRNA [37, 38] . Extension of this study to evaluate the eVect of multiple drugs in combination on polyamine catabolism showed that a combination of 5-FU and oxaliplatin pre-treatment followed by treatment with BENSpm induced signiWcantly higher levels of SSAT and SMO mRNA, protein and activity and resulted in greater depletion of spermine and spermidine pools than was observed when treated with oxaliplatin or 5-FU alone. It is noted that oxaliplatin/BENSpm combinations were more eVective at SSAT induction than 5-FU/BENSpm [38] . However, these results are in contrast to a recent study that examined two asymmetrically substituted polyamine analogues,
, in combination with similar cytotoxic agents in breast cancer using the same treatment schedules [33] . In that study, the most synergy was seen when cells were treated with the cytotoxic drug alone for 24 h followed by polyamine analogue treatment alone for 96 h, while the concomitant treatment schedule was predominantly additive or antagonistic in the breast cancer cell lines examined. Importantly, several of the previously reported experiments that found synergy by pre-treating with the cytotoxic drug were repeated using CPENSpm and CHENSpm and similar CI values were obtained (data not shown). This suggests that the diVerence in results for various schedules between these two studies is primarily polyamine analogue-dependent. Although all of these analogues have anti-tumor activity, they have diVerent mechanisms of action. CHENSpm and CPENSpm induce programmed cell death by altering tubulin polymerization or super-inducing the polyamine catabolic enzyme SSAT, respectively [12, 31, 73] , while the treatment of breast cancer cell lines with BENSpm induces a G1 arrest that is associated with an induction of SSAT and SMO in a cell line-dependent manner [57] . The variable mechanisms of action of each of these analogues enable them to have a distinct ability to synergize with speciWc agents in a schedule-dependent manner.
BENSpm was not as eVective when the cells were Wrst treated with the cytotoxic agent alone. Treatment with the cytotoxic followed by BENSpm generally resulted in additivity or antagonism. This schedule-dependency is well documented in studies of other combinations. One study examining the combination of paclitaxel and vinorelbine using the human doxorubicin-resistant MCF-7 human breast carcinoma cell line found synergistic eVects when the drugs were administered simultaneously [21] . However, when the drugs were administered sequentially, antagonistic eVects resulted. Another study examined paclitaxel in combination with pemetrexed (folate antimetabolite) in MCF-7 cells and found an additive/antagonistic eVect with simultaneous treatment, a synergistic eVect for pemetrexed followed by paclitaxel, and an additive eVect for paclitaxel followed by pemetrexed [44] . The mechanisms involved in the schedule-dependency of these agents are not yet known, although it is hypothesized that cell cycle accessibility is a major cause of additivity, antagonism and synergy. Exposure to the cytotoxic agent Wrst may not only aVect or alter the molecular targets of the polyamine analogue, but may prevent entry of the cell into the phase of the cell cycle required for activity of the polyamine analogue. The ability of BENSpm to synergize with cytotoxic agents using a concomitant treatment schedule is desirable since it is the most convenient combination treatment regimen in a clinical setting.
Of the cytotoxic agents evaluated, the two Xuoropyrimidines, FdUrd and 5-FU, and paclitaxel were the most synergistic in the human breast cancer cell lines studied here. It is not known why these agents are so synergistic with BENSpm. The Xuoropyrimidines were also found to be among the most synergistic agents with CPENSpm and CHENSpm in a previous study, but this is the Wrst report of synergy between paclitaxel and a polyamine analogue [33] . It seems unlikely that stage of cell cycle is responsible for the synergy since FdUrd and 5-FU are reported to induce a G1 block whereas paclitaxel induces a G2/M block [29, 48, 54] . Also although paclitaxel and docetaxel are both Mice bearing tumors generated by subcutaneous injection of MDA-MB-231 breast cancer cells were randomly divided into groups of 10 and treated intraperitoneally with either BENSpm alone (100 mg/kg) for 5 days each week, paclitaxel alone (5 mg/kg weekly) or BENSpm/ paclitaxel or control for a study period of 4 weeks. Treatment schedule is described in Materials and methods. Time-to-6 fold tumor growth relative to baseline was evaluated using cumulative incidence function accounting for the presence of competing risks and represented graphically tubulin-interfering agents, docetaxel did not synergize with BENSpm, suggesting that the G2/M block is not related to the synergy or antagonism of the combination. Both docetaxel and vinorelbine treatment result in a G2/M block and neither one of these agents synergized well with BENSpm in either cell line examined.
Two ER-negative breast cancer cell lines, MDA-MB-231 and Hs578t, two ER-positive breast cancer cell lines, MCF-7 and T47D, and one immortalized non-tumorigenic mammary epithelial cell line, MCF-10A, were utilized in this study. Findings were schedule-and agent-speciWc, but the patterns of synergy overall were not cell-line speciWc. FdURd, 5-FU, and paclitaxel were generally synergistic with BENSpm in all four cancer cell lines whereas C-DDP, docetaxel, and vinorelbine were commonly additive or antagonistic with BENSpm in each cancer cell line. The diVerences in synergy between the cancer cell lines and the non-tumorigenic cell line are noteworthy. The greatest synergy overall was seen with BENSpm in combination with 5-FU, FdUrd, and paclitaxel in the four cancer cell lines examined. When a concomitant treatment schedule was used, BENSpm was antagonistic with both 5-FU and FdURd in MCF-10A cells and was mildly synergistic with paclitaxel. However, the CI value for BENSpm and paclitaxel was higher in MCF-10A cells versus the cancer cell lines examined, suggesting that a diVerential sensitivity exists between the tumorigenic and non-tumorigenic cell lines.
Comparing the synergy seen with diVerent breast cancer cell lines, BENSpm showed the most promise in combination with 5-FU and paclitaxel. The cytotoxic eVects of several polyamine analogues are attributed to induction of the polyamine catabolic enzymes, SSAT and SMO [13, 24, 26, 58] . Recently, BENSpm was shown to induce SSAT and SMO activity in breast cancer cell lines in a cell-line dependent fashion [57] . DNA microarray technology was used to identify genes transcriptionally activated by 5-FU in MCF-7 cells, and SSAT was found to be among the most transcriptionally induced genes in 5-FU treated MCF-7 cells [51] . Additional studies have reported the ability of other chemotherapeutic agents to induce SSAT and SMO mRNA expression [17, 37] . For these reasons, we examined the role of the polyamine catabolic enzymes, SSAT and SMO, in the synergistic response of breast cancer cell lines to BENSpm treatment with 5-FU or paclitaxel.
BENSpm, 5-FU, and paclitaxel each induced SSAT mRNA in a dose-and time-dependent manner in both MDA-MB-231 and MCF-7 cells. Interestingly, both chemotherapeutic agents induced greater SSAT mRNA than BENSpm treatment alone in each cell line; however, neither of these agents alone induced signiWcant SSAT activity (Fig. 1) . These results are consistent with a study that examined the ability of platinum drugs to induce polyamine catabolic enzymes in ovarian cancer cell lines [37] . This study in A2780 ovarian cancer cells demonstrated the ability of platinum drugs to induce SSAT mRNA, which was only translated into SSAT protein with co-or post-treatment with BENSpm. Based on these studies, it appears that several chemotherapeutic agents are able to induce SSAT mRNA although co-treatment with BENSpm appears to be required for its translation into protein. These results are consistent with the hypothesis that large increases in SSAT protein and activity are regulated at the post-transcriptional level [20] . It is reported that the transcriptional activation of SSAT is not due to enhanced BENSpm uptake but possibly through inactivation of IkB [18] . In contrast, SMO induction in MDA-MB-231 cells in response to BENSpm, 5-FU, or paclitaxel occurred at both the mRNA and activity level (Fig. 2) . Time course studies revealed that induction of SMO mRNA and activity began within six hours of treatment with each agent (data not shown). These results are consistent with the recent Wnding that most SMO regulation occurs at the level of mRNA [72] .
Induction of SSAT is known to be a general stress response to a variety of factors and environmental conditions [56] . The possibility that the induction of SSAT, and perhaps other polyamine catabolic enzymes, represents a general response to environmental stress rather than a speciWc response to the chemotherapeutic agents selected was addressed by performing experiments using another chemotherapeutic agent, vinorelbine. Vinorelbine, was predominantly additive or antagonistic with BENSpm in several breast cancer cell lines (data not shown). Treatment of MDA-MB-231 or MCF-7 cells with vinorelbine over a similar dose-response and time-course did not signiWcantly induce SSAT, APAO, or SMO mRNA or activity (data not shown). This Wnding suggests that the high induction of SSAT and SMO mRNA resulting from 5-FU or paclitaxel treatment is not solely a general stress response; rather the polyamine catabolic pathway may be a primary target of the chemotherapeutic agents that synergize with BENSpm.
Stable knock down of SSAT, SMO or both in MDA-MB-231 and MCF-7 cells by RNA interference was used to determine what role these enzymes play in the synergistic response of each cell line to treatment with BENSpm and 5-FU or paclitaxel. The knockdown of each enzyme alone partially reduced the sensitivity of MDA-MB-231 cells to BENSpm treatment with 5-FU or paclitaxel while MDA-MB-231 SSAT/ SMO cells were the most resistant. While SSAT and SMO were found to play a major role in the response of MDA-MB-231 cells to treatment with BENSpm plus 5-FU or paclitaxel, these enzymes do not appear to play as great a role in the response of MCF-7 cells to these treatments. Neither SMO mRNA nor activity was induced by any of these agents in MCF-7 cells while SSAT played a modest role in response to BENSpm and paclitaxel and a greater role in the response to BENSpm with 5-FU. It will be important to examine the eVects of these agents on the activity of ODC, one of the rate-limiting enzymes in polyamine biosynthesis, since BENSpm alone signiWcantly reduces ODC activity in this cell line and because these agents often aVect multiple polyamine metabolic enzymes. However, recent data demonstrated the ability of BENSpm and 5-FU to synergistically induce SSAT mRNA in human colon cancer cell lines; this induction was associated with a synergistic induction of apoptosis in wild-type and p53-null HCT116 colon carcinoma cells [17] . Transcriptome analysis from this study demonstrated that BENSpm and 5-FU treatment decreased the mitochondrial membrane potential, activated caspase 9, and led to the release of cytochrome c in both cell lines [17] . However, alteration in levels and metabolism of polyamines may not be completely responsible for cytotoxicity and induction of apoptosis. It was recently reported that BENSpm eVectively induces apoptosis in chondrocytes independently of polyamine metabolism and levels [66] .
BENSpm inhibits polyamine biosynthetic enzymes, induces polyamine catabolic enzymes like SSAT and SMO and inhibits cell growth in several diVerent cancer cell lines in vitro [6] . Consistent antitumor activity has also been reported in several xenograft models. BENSpm given at 40 mg/kg 3 times/day for 6 days i.p. suppresses tumor growth of MALME-3 M human melanoma xenografts during treatment and up to 65 days after exposure [5] . Tumor regression was observed in other human solid tumor xenografts including A121 ovarian carcinoma, HT29 colon carcinoma, and SH-1 melanoma on i.p. treatment with 40-80 mg/kg BENSpm 3 times a day for 4 days [6] and in xenograft mouse models of pancreatic [15] , bladder [62] and prostate cancer cell lines [60, 75] .
In our study treatment of mice bearing MDA-MB-231 cell xenografts with BENSpm at 100 mg/kg/day 5 times a week for 4 weeks resulted in a signiWcant decrease in tumor growth. SigniWcant tumor regression was also evident with combination treatment with BENSpm and paclitaxel, although no synergism between the drugs was seen. Although 100 mg/kg BENSpm and weekly 5 mg/kg paclitaxel are both eVective doses for tumor growth inhibition in breast carcinoma xenograft models, the treatment schedule chosen may not be the best to elicit a synergistic response. The lack of synergy observed may well be due to pharmacokinetic parameters that cannot be eVectively modeled in vitro; this will necessitate additional experimentation to identify synergistic treatment schedules. Also, as treatment with 100 mg/kg/day of BENSpm in the schedule chosen was extremely eVective, it may be possible to reduce the dose and/or frequency of BENSpm administration, thus reducing the possibility of potential toxicities and increasing the potential for synergy with paclitaxel. Finally, it is possible that sequential treatment may be more eVective than the concurrent treatment used here. Thus, this study forms the basis for further exploration of optimal dose and schedule of combinative studies with cytotoxic drugs and BENSpm in vivo in preparation for human testing.
It is important to note that the data provided here may also be helpful in the development of combination treatment strategies with newly introduced polyamine analogues. One such agent, CGC-11047, that demonstrated eVective antitumor properties in preclinical studies is currently in clinical trial [32] . The present study will form a platform for future studies of CGC-11047 in combination with chemotherapeutics that induce SSAT and/or SMO that could be translated clinically.
In conclusion, this study demonstrates that 5-FU or paclitaxel induces SSAT and SMO mRNA expression, and cotreatment with BENSpm leads to a large induction of SSAT and SMO activity in two representative human breast cancer cell lines. Knockdown studies suggest that induction of SSAT and SMO is correlated with the antiproliferative eVects of BENSpm with 5-FU or paclitaxel in MDA-MB-231 cells. The induction of SSAT and SMO appears to play a speciWc role in the synergistic response of breast cancer cell lines to BENSpm with paclitaxel and 5-FU but not another chemotherapeutic, vinorelbine, suggesting speciWcity of eVect. These results provide evidence that combining standard chemotherapeutic agents with polyamine analogues that induce SSAT and SMO is a rational approach to treating breast cancer. With further optimization of polyamine analogues and schedules, these results may lead to clinically relevant treatment strategies.
